Changes in exhaled nitric oxide (eNO) over time in stable lung transplant recipients without chronic rejection Source: Eur Respir J 2003; 22: Suppl. 45, 327s Year: 2003
Comparison of hemodynamic effects of inhaled nitric oxide (iNO) and inhaled epoprostenol (iEPO) in patients with pulmonary hypertension (PH) Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011
Exhaled nitric oxide (eNO) and lung transplantation (LTx): impact of the native lung? Source: Eur Respir J 2001; 18: Suppl. 33, 179s Year: 2001
Effects of posttransplant bronchiolitis obliterans syndrome (BOS) on exhaled nitric oxide (eNO) Source: Annual Congress 2003 - Bronchiolitis obliterans: diagnosis and treatment Year: 2003
Exhaled nitric oxide after lung transplantation: impact of the native lung Source: Eur Respir J 2003; 21: 429-432 Year: 2003
Exhaled carbon monoxide correlates with airway neutrophilia in patients with chronic allograft dysfunction (BOS) after lung transplantation Source: Annual Congress 2007 - New insights into clinical lung transplantation Year: 2007
Fractional exhaled nitric oxide (FeNO) could be a good predictor for the effectiveness of inhaled corticosteroid (ICS) in patients with COPD Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009
Changes in nitric oxide (NO) cycle metabolites in children with mild asthma (BA) receiving STEP-2 therapy Source: Virtual Congress 2020 – Novel mechanisms and management of paediatric asthma Year: 2020
Exhaled NO concentration (FENO ) in patients listed for a liver transplantation Source: Eur Respir J 2005; 26: Suppl. 49, 350s Year: 2005
Azithromycin (Azi) treatment for chronic allograft dysfunction after lung transplantation (LTx) Source: Annual Congress 2003 - Bronchiolitis obliterans: diagnosis and treatment Year: 2003
Stability of exhaled nitric oxide (FE NO) in patients with severe, steroid-dependent asthma Source: Annual Congress 2008 - Clinical utility of exhaled nitric oxide measurement Year: 2008
Benefit of inhaled corticosteroids (ICS) in asthmatic patients with bronchial hyperresponsiveness (BHR) to mannitol and low fractional exhaled nitric oxide (FeNO) levels Source: International Congress 2017 – Monitoring asthma control Year: 2017
Can fractional exhaled nitric oxide be useful to differentiate asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) from COPD-only Source: Virtual Congress 2020 – Air pollution and comorbidities Year: 2020
Optimising inhaled corticosteroid (ICS) dose using exhaled nitric oxide (eNO) measurements Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003
Cough sensitivity, airway responsiveness and exhaled nitric oxide (eNO) for predicting the response to bronchodilator therapy (BDT) in patients with chronic non-productive cough Source: Annual Congress 2010 - Cough, airway hyperresponsiveness and asthma control Year: 2010
Relationship between baseline fraction of exhaled nitric oxide (FeNO) and response to anti-IL-5/5R therapies in severe eosinophilic asthma (SEA) Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Adult asthma, fraction of exhaled nitric oxide (FENO ), and lung function Source: Annual Congress 2009 - Epidemiology of asthma Year: 2009
Fractional exhaled nitric oxide (FeNO) suppression with directly observed inhaled corticosteroid therapy: does it make a difference to patient outcomes? Source: International Congress 2018 – Clinical and functional monitoring in airway disease Year: 2018
A 2-year follow-up of exhaled nitric oxide (FeNO) and pulmonary function tests in young patients with cystic fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 538s Year: 2001
Diagnostic use of exhaled nitric oxide (eNO) after lung transplantation Source: Eur Respir J 2006; 28: Suppl. 50, 723s Year: 2006